Physician

Hematology

Dr. Charles A. Coltman, MD

Doctor Charles A. Coltman, MD works in the field of Hematology. He graduated from University of Pittsburgh School of Medicine. He has 1 awards "Fellow (FASCO)". Doctor Charles A. Coltman, MD is a published doctor as well. He has 26 publications published. The latest was: Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.

Publications

Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.
Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.
Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.
Does the level of prostate cancer risk affect cancer prevention with finasteride?
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial.
Finasteride decreases the risk of prostatic intraepithelial neoplasia.
Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
The prostate cancer prevention trial: design, biases and interpretation of study results.
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials.
Erectile dysfunction and subsequent cardiovascular disease.
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
Estimated impact of the Prostate Cancer Prevention Trial on population mortality.
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies.
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
Implementation of the Prostate Cancer Prevention Trial (PCPT).
Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture.
The influence of finasteride on the development of prostate cancer.

Schools

University of Pittsburgh School of Medicine
Del Hospital
Ohio State University Hospital

Doctors Specialties

Hematology
Medical Oncology
Oncology

Accepted Insurances

Awards

Fellow (FASCO)

Education

Ohio State University Hospital
University of Pittsburgh School of Medicine

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Suneetha Challagundla, MD This Doctor is OpenDoctor Recommended.
	Dr. Syed N. Raza, MD
	Dr. Richard M. Elledge, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Joseph D. McCracken, MD This Doctor is OpenDoctor Recommended.
	Dr. Robert A. Marciniak, MD This Doctor is OpenDoctor Recommended.
	Dr. Russell A. Baur, MD This Doctor is OpenDoctor Recommended.
	Dr. Kuang M. Chang, MD
	Dr. Joseph My, DO
	Dr. Laeeq A. Malik, MD This Doctor is OpenDoctor Recommended.
	Dr. Devalingam Mahalingam, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Michael A. Wiggins, MD
	Dr. Seema G. Naik, MD This Doctor is OpenDoctor Recommended.